SUBSCRIBE
SUBSCRIBE
News   Policy

Amylin Pharmaceuticals, Inc. Says Key Diabetes Drug to Launch this Year

January 28, 2010 | 
1 min read
Bookmark and Share

Reuters -- Amylin Pharmaceuticals Inc said on Wednesday it expects to begin selling the long acting version of its Byetta diabetes drug this year and sees "a clear path to sustained profitability."
Regulatory
MORE ON THIS TOPIC
Racing Cars at the finish line
Approvals
Ascendis Enters Achondroplasia Arena as FDA Approves First Weekly Drug
March 2, 2026
 · 
2 min read
 · 
Tristan Manalac
Pictured: Front view of the CDC museum in Georgia
CDC
RFK Jr. Appoints 2 New Advisors to CDC Vaccine Panel Ahead of March Meeting
March 2, 2026
 · 
2 min read
 · 
Tristan Manalac
A scientist with pill bottles in front of FDA headquarters
Regulatory
FDA Action Alert: BMS, GSK, Aldeyra and More
March 2, 2026
 · 
4 min read
 · 
Tristan Manalac
Borrow money from friend, debt and loan, incentive or bonus payment, credit or lending concept, businessman hand giving money banknote to friend's hand.
FDA
FDA To Offer Bonus Payments for Speedy Drug Reviewers
February 27, 2026
 · 
1 min read
 · 
Annalee Armstrong